Effect of Morus Alba leaves’s extract supplement on type 2 diabetes

Effect of Morus Alba leaves’s extract supplement on blood glucose, lipid profiles, HbA1c, insulin resistance ,inflammation factors and oxidative stress biomarkers in patients with type 2 diabetes

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016081312438N21

Enrollment

Registered

2017-01-12

Start date

2016-11-21

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabets type 2. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: Intervention group:300 mg Morus Alba leaves’s extract capsule, twice a day

12 weeks

produced by Barij esans Co, Kashan, Iran. Intervention 2: Control group: Placebo capsule

twice a day

produced by Barij esans Co, Kashan, Iran.

Eligibility

Sex/Gender

All

Age

35 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes mellitus Aged 35–70 years

Exclusion criteria

Exclusion criteria: Mulberry extract intake in the last three months Changing in glucose-lowering medications Taking anticoagulants during the study Pregnancy or lactating Malignancies Chronic hepatic diseases

Design outcomes

Primary

Measure	Time frame
HOMA-IR. Timepoint: Before the beginning of the study and 12 weeks after. Method of measurement: Calculated with HOMA formula.	—

Secondary

Measure	Time frame
Fasting plasma glucose (FPG). Timepoint: Before the beginning of the study and after 12 weeks. Method of measurement: Enzymatic.;Insulin. Timepoint: Before the beginning of the study and after 12 weeks. Method of measurement: ELISA.;QUICKI. Timepoint: Before the beginning of the study and after 12 weeks. Method of measurement: Calculated with formula.;HbA1C. Timepoint: Before the beginning of the study and after 12 weeks. Method of measurement: Immunofluorescence.;Triglycerides. Timepoint: Before the beginning of the study and after 12 weeks. Method of measurement: Enzymatic.;Very low density lipoptotein (VLDL)-Cholesterol. Timepoint: Before the beginning of the study and after 12 weeks. Method of measurement: Enzymatic.;Cholesterol. Timepoint: Before the beginning of the study and after 12 weeks. Method of measurement: Enzymatic.;Low density lipoptotein (LDL)-Cholesterol. Timepoint: Before the beginning of the study and after 12 weeks. Method of measurement: Enzymatic.;High density lipoptotein (HDL)-Cholesterol. Timepoint: Before the beginning of the study and after 12 weeks. Method of measurement: Enzymatic.;Alanine transaminase (ALT). Timepoint: Before the beginning of the study and after 12 weeks. Method of measurement: Enzymatic.;Aspartate transaminase (AST). Timepoint: Before the beginning of the study and after 12 weeks. Method of measurement: Enzymatic.;C reactive protein (CRP). Timepoint: Before the beginning of the study and after 12 weeks. Method of measurement: ELISA.;Nitric oxide (NO). Timepoint: Before the beginning of the study and after 12 weeks. Method of measurement: Spectrophotometry.;Total antioxidant capacity (TAC). Timepoint: Before the beginning of the study and after 12 weeks. Method of measurement: Spectrophotometry.;Glutathione (GSH). Timepoint: Before the beginning of the study and after 12 weeks. Method of measurement: Spectrophotometry.;Malondialdehyde (MDA). Timepoint: Before the beginning of the study and after 12 weeks. Method of meas	—

Measure

Time frame

Fasting plasma glucose (FPG). Timepoint: Before the beginning of the study and after 12 weeks. Method of measurement: Enzymatic.;Insulin. Timepoint: Before the beginning of the study and after 12 weeks. Method of measurement: ELISA.;QUICKI. Timepoint: Before the beginning of the study and after 12 weeks. Method of measurement: Calculated with formula.;HbA1C. Timepoint: Before the beginning of the study and after 12 weeks. Method of measurement: Immunofluorescence.;Triglycerides. Timepoint: Before the beginning of the study and after 12 weeks. Method of measurement: Enzymatic.;Very low density lipoptotein (VLDL)-Cholesterol. Timepoint: Before the beginning of the study and after 12 weeks. Method of measurement: Enzymatic.;Cholesterol. Timepoint: Before the beginning of the study and after 12 weeks. Method of measurement: Enzymatic.;Low density lipoptotein (LDL)-Cholesterol. Timepoint: Before the beginning of the study and after 12 weeks. Method of measurement: Enzymatic.;High density lipoptotein (HDL)-Cholesterol. Timepoint: Before the beginning of the study and after 12 weeks. Method of measurement: Enzymatic.;Alanine transaminase (ALT). Timepoint: Before the beginning of the study and after 12 weeks. Method of measurement: Enzymatic.;Aspartate transaminase (AST). Timepoint: Before the beginning of the study and after 12 weeks. Method of measurement: Enzymatic.;C reactive protein (CRP). Timepoint: Before the beginning of the study and after 12 weeks. Method of measurement: ELISA.;Nitric oxide (NO). Timepoint: Before the beginning of the study and after 12 weeks. Method of measurement: Spectrophotometry.;Total antioxidant capacity (TAC). Timepoint: Before the beginning of the study and after 12 weeks. Method of measurement: Spectrophotometry.;Glutathione (GSH). Timepoint: Before the beginning of the study and after 12 weeks. Method of measurement: Spectrophotometry.;Malondialdehyde (MDA). Timepoint: Before the beginning of the study and after 12 weeks. Method of meas

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.M. Taghizadeh

Barij Research Center of Medicinal Herbs

mohsenta44@yahoo.com+98 86 4446 5112

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 18, 2026